Eisai Co., Ltd.TSE: 4523

FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

· Issued by Eisai Co., Ltd. via TDnet
Watch Eisai explain itEisai Co Ltd (ESALF) Q1 2027 Earnings Call · Replay · Aug 3

Eisai Co., Ltd. (4523) Press Release

View Attachment

Earlier from Eisai

All Eisai news releases